Prof Dr. Michael Linnebacher | Healthcare Applications | Best Researcher Award

Posted on by ScienceFather

Prof Dr. Michael Linnebacher | Healthcare Applications | Best Researcher Award

Prof Doctorate at Universitätsmedizin Rostock, Germany 

Profiles

Scopus

Orcid

Summary:

Prof Dr. Michael Linnebacher, born on July 5, 1969, in Ottweiler, Germany, is a prominent researcher in molecular oncology and immunotherapy. He serves as the Laboratory and Research Director at the Clinic for General Surgery, University Medicine Rostock. Linnebacher’s career spans significant contributions to the understanding and treatment of gastrointestinal tumors, particularly focusing on immunotherapy and the role of microsatellite instability in cancer.

Education

Prof Dr. Linnebacher holds a Diploma in Biology from the University of Saarland (1996) and completed his PhD in Biology at the Technical University of Karlsruhe in 2001. His academic training includes extensive research on immunogenic neo-peptides and tumor antigens, setting a strong foundation for his career in oncology and immunotherapy.

💼 Professional Experience

  • 1996-1997: Research assistant, Heidelberg University Biochemistry Center
  • 1998-2001: PhD student, Institute of Immunology, Ruprecht-Karls-University Heidelberg
  • 2001-2005: Postdoctoral research, University Hospital Heidelberg, Department of Molecular Pathology
  • 2005-Present: Laboratory Director, Molecular Oncology and Immunotherapy, Clinic for General Surgery, University Medical Center Rostock
  • 2009: Venia legendi (Privatdozent)
  • 2010: Junior Professor for Immunology and Infectiology, University of Saarland
  • 2012: Professor for Translational Surgical Oncology and Biobanking, University of Lübeck
  • 2020-Present: Managing Director, BioBank Rostock; Member of the German Biobank Alliance

🔬 Research Interests

  • Immunotherapy and its applications in cancer treatment
  • Microsatellite instability and its role in tumor antigen development
  • Translational research in oncology
  • Biobanking and its role in cancer research and treatment

 

Publications

Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells

  • Authors: Schwarz, S., Su, Z., Krohn, M., Schlosser, A., Linnebacher, M.
  • Journal: npj Precision Oncology
  • Year: 2024

Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy

  • Authors: Edelmann, M., Fan, S., De Oliveira, T., Rieken, S., Conradi, L.-C.
  • Journal: Cancer Research Communications
  • Year: 2024

Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer

  • Authors: Mariella, E., Grasso, G., Miotto, M., Di Nicolantonio, F., Bardelli, A.
  • Journal: Molecular Oncology
  • Year: 2024

SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation

  • Authors: Yuan, J., Zhu, Z., Zhang, P., Gong, P., Zhang, X.
  • Journal: Cancer Letters
  • Year: 2024

A glutamatergic biomarker panel enables differentiating Grade 4 gliomas/astrocytomas from brain metastases

  • Authors: Lange, F., Gade, R., Einsle, A., Freiman, T.M., Kirschstein, T.
  • Journal: Frontiers in Oncology
  • Year: 2024

Ms. Rebekah Fretwell | Healthcare Applications | Best Researcher Award

Posted on by ScienceFather

Ms. Rebekah Fretwell | Healthcare Applications | Best Researcher Award

Rebekah Fretwell at Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom

Profile

Scopus

Education

  • Doctorate Degree: Thesis submission due December 2024
  • MSc Pathological Sciences: University of Sheffield, 2005
  • BSc (Hons) Medicine & Pharmacology: University of Sheffield, 2003
  • A-Levels: Biology, Chemistry, English Literature, General Studies (1999)
  • GCSEs: 13 subjects including Biology, Chemistry, and Mathematics (1997)

💼 Professional Experience

  • Current Position: Senior Specialist Biomedical Scientist in Coagulation; ADAMTS-13 Section Lead; Lead Training Manager at Royal Hallamshire Hospital and Northern General Hospital, Sheffield
  • Past Roles: Union Representative for Department of Medicine & Pharmacology, University of Sheffield (2001-2003)

🔬 Research Interests

  • Recent Projects:
    • Developing automated ADAMTS-13 activity assays (2023-2024) 
    • Assessing Factor Xa inhibitors and their reversal (2012-present) 
    • Evaluating effects of Direct Thrombin Inhibitors (2004-2005) 
  • Key Contributions:
    • Setting up ADAMTS-13 activity and antibody assays 
    • Research into FVIII Inhibitor assays and new anticoagulant therapies 

🌐 Professional Membership

  • Member: Institute of Biomedical Science (MIBMS) 

📚 Teaching and Mentoring

  • Lecturer: BSc & MSc courses at University of Sheffield, Sheffield Hallam University, and Bradford University 
  • Practice Tutor/Assessor: University of Hull, supervising and assessing students in biomedical science placements

 

Publications

Practical Considerations for the Use of the Rapid AcuStar® ADAMTS13 Activity Assay in the Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP)

  • Authors: Yong, J., MacDonald, S., Downey, C., Pitchford, T., Dutt, T.
  • Journal: Journal of Clinical Medicine
  • Year: 2024

Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study)

  • Authors: Sumaya, W., Parker, W.A.E., Fretwell, R., Ajjan, R.A., Storey, R.F.
  • Journal: Thrombosis and Haemostasis
  • Year: 2018

Multiple Centre Evaluation Study of ADAMTS13 Activity and Inhibitor Assays

  • Authors: Langley, K., Fretwell, R., Kitchen, S., Murphy, P., Scully, M.
  • Journal: International Journal of Laboratory Hematology
  • Year: 2018